{"id":"W2511120040","doi":"10.1016/s0140-6736(16)31322-8","title":"Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":1379,"is_retracted":false,"has_abstract":false,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton; Vancouver General Hospital","funders":"Wake Forest School of Medicine; Teva Pharmaceutical Industries; AstraZeneca","keywords":"Benralizumab; Medicine; Placebo; Mepolizumab; Asthma; Exacerbation; Internal medicine; Clinical endpoint; Eosinophil; Gastroenterology; Randomized controlled trial; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}